Renal Progenitor Cells
AssigneeThe University of Queensland
InventorsMelissa LITTLE, Minoru TAKASATO
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe University of Queensland
InventorsMelissa LITTLE, Minoru TAKASATO
Estimating the term…
A method is provided for simultaneously producing both nephron progenitor cells and ureteric epithelial progenitor cells including the step of contacting intermediate mesoderm cells with: fibroblast growth factor (9) and/or fibroblast growth factor (20) and optionally, one or more selected from the group consisting of. bone morphogenic protein 7; heparin: a Wnt agonist; retinoic acid; and an RA antagonist. The concentrations of Writ agonist, retinoic acid and/or RA antagonist may be manipulated to favour the relative production of nephron progenitor cells and ureteric epithelial progenitor cells. The intermediate mesoderm cells are ultimately derived from human pluripotent stem cells via a posterior primitive streak stage. The nephron progenitor cells and ureteric epithelial progenitor cells may have end uses such as for kidney repair and regeneration, bioprinting of kidneys and screening compounds for nephrotoxicity.
A method of producing nephron progenitor cells and ureteric epithelial progenitor cells comprising contacting intermediate mesoderm (IM) cells with:
3-9. (canceled)
11-12. (canceled)
(canceled)
22-23. (canceled)
26-27. (canceled)
A method of making kidney tissue, comprising bioprinting isolated or purified nephron progenitor cells and ureteric epithelial progenitor cells and differentiating said nephron progenitor cells and ureteric epithelial progenitor cells.
A method of making kidney tissue, comprising incorporating isolated or purified nephron progenitor cells and ureteric epithelial progenitor cells into a whole organ decellularised kidney, and differentiating said nephron progenitor cells and ureteric epithelial progenitor cells.
A method of producing nephron progenitor cells and ureteric epithelial progenitor cells, comprising culturing hPSCs with a Wnt agonist followed by culturing the cells with FGF9.
Dependencies are inferred from the claim text.